Last reviewed · How we verify

Calvan — Competitive Intelligence Brief

Calvan (BEVANTOLOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: bevantolol. Area: Cardiovascular.

marketed bevantolol Beta-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Calvan (BEVANTOLOL).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Calvan TARGET BEVANTOLOL marketed bevantolol Beta-1 adrenergic receptor
Onoact LANDIOLOL Aop Hlth Us marketed landiolol Beta-1 adrenergic receptor 2024-01-01
Betaxon LEVOBETAXOLOL Alcon Pharms Ltd marketed levobetaxolol Beta-1 adrenergic receptor 2000-01-01
Genesa ARBUTAMINE marketed arbutamine Beta-1 adrenergic receptor 1997-01-01
Zebeta BISOPROLOL Teva marketed beta-Adrenergic Blocker Beta-1 adrenergic receptor 1992-01-01
Levadil DILEVALOL marketed dilevalol Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Beta-1 adrenergic receptor 1990-01-01
Optipranolol METIPRANOLOL Bausch Health marketed beta-Adrenergic Blocker Beta-1 adrenergic receptor 1989-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (bevantolol class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Calvan — Competitive Intelligence Brief. https://druglandscape.com/ci/bevantolol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: